Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects

详细信息    查看全文

• 作者：Tsuyoshi Yanagimachi¹ ; Yukihiro Fujita¹ ; ^{yfujita@asahikawa-med.ac.jp} ; Yasutaka Takeda¹ ; Jun Honjo¹ ; Hidemitsu Sakagami¹ ; Hiroya Kitsunai¹ ; Yumi Takiyama¹ ; Atsuko Abiko¹ ; Yuichi Makino¹ ; Timothy J. Kieffer² ; Masakazu Haneda¹
• 关键词：Receptor-mediated incretin bioassays ; Glucose-dependent insulinotropic polypeptide ; Glucagon-like peptide-1 ; Dipeptidyl peptidase-4
• 刊名：Molecular Metabolism
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：6
• 期：2
• 页码：226-231
• 全文大小：520 K
• 卷排序：6

文摘

Receptor-mediated bioassays were used to measure GIP and GLP-1 in humans. The GIP bioassay, but not two ELISAs, detected both GIP(1–42) and GIP(1–30)NH2. Active GIP levels were increased more than GLP-1 after DPP-4 inhibitor treatment.